Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhen you stop taking Wegovy, appetite typically returns to its pre-treatment level within days to weeks, and weight regain is common without ongoing clinical and lifestyle support. This is not a personal failing — semaglutide works on biological pathways that suppress hunger, and once the medicine leaves your system, those signals reassert themselves. Wegovy is a prescription-only medicine that requires clinical assessment to start or continue, and any decision to pause or stop should involve your prescriber rather than happen abruptly.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide has a half-life of roughly one week, which means it takes several weeks to clear your system entirely after the final injection. During that window you may notice hunger returning gradually rather than all at once. Gastric emptying speeds back up, satiety signals weaken, and the mental quieting of food noise (the persistent thoughts about eating that many people describe as the most noticeable benefit) begins to fade. For most people this process unfolds over one to three weeks rather than overnight.
There is no withdrawal syndrome in the pharmacological sense. You will not experience shivering, sleep disruption or cravings of the kind associated with stopping certain other medicines. What does happen is biological: the suppression that was doing a lot of the heavy lifting simply stops. That distinction matters, because it means the challenge ahead is metabolic and behavioural rather than medical.
If you have been rotating injection sites carefully (abdomen, thigh, upper arm) you can stop without any taper. The pen sitting in the fridge door does not need to be finished if your prescriber has advised you to stop. Dispose of used pens and needles safely using a sharps container.
The STEP 1 extension study is the clearest evidence we have. Adults who completed 68 weeks of semaglutide 2.4mg had lost around 15% of their body weight on average; one year after stopping, roughly two-thirds of that loss had returned. By month 12 post-treatment, most participants had regained a substantial portion of their original weight. The STEP 1 trial, published in the New England Journal of Medicine, and its follow-up data make clear that this is a consistent pattern rather than an individual outlier experience.
The reason is not mysterious. Obesity is a chronic condition shaped by hormones, genetics and environment. Semaglutide manages it the way blood-pressure medication manages hypertension, effectively, while you take it. When you stop, the underlying biology reasserts itself. The NHS guidance on semaglutide frames it this way too: long-term use may be needed for sustained effect, and any changes to your treatment plan should be made with clinical input.
If you are weighing the long-term picture, what happens after you stop taking Wegovy, from hunger returning to the longer weight trajectory, is an important part of that conversation with your prescriber.
There are legitimate reasons to stop: pregnancy, surgery, a change in your health circumstances, or simply a personal choice. What matters is how the stop is handled. Practically, the people who maintain the most progress after stopping are those who have built consistent eating habits and regular activity into daily life during treatment, not those who relied on the medicine alone.
NICE's recommendation for semaglutide (TA875) specifically ties it to use within a specialist weight management service with multidisciplinary support, in part because that wraparound care is what protects the outcomes. Even on a private prescription, working with your prescriber on a realistic plan (protein intake, portion habits, movement) before stopping gives you a significantly better starting position.
If cost is a factor in whether to continue, what Wegovy costs privately in the UK is worth looking at in full context, since the total picture includes what clinical supervision and aftercare are included in what you pay. A short pause of a fortnight has its own specific implications; stopping Wegovy for two weeks is covered in more detail separately.
The most important practical step is this: tell your prescriber before you stop, not afterwards. If you are on a phased dose schedule and considering stopping mid-titration, your prescriber can advise whether a slower wind-down or a pause at your current dose makes more sense for your situation. If you have comorbidities that the treatment was also helping to manage (blood pressure, blood sugar) those need monitoring after you stop too.
At nume, every patient has a real prescriber reviewing their treatment, not a form routed to a software system. Questions about stopping, pausing, or switching are exactly the kind of thing our clinical team handles through our priority aftercare, seven days a week. If you are still exploring whether Wegovy is the right starting point, the injection technique and practical use guide gives a grounded sense of what the treatment involves day to day. And if you are at an earlier stage and weighing your options, an overview of the weight-loss treatments we offer sets out the full picture. A free consultation is the starting point if you want a prescriber's view on your specific circumstances.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.